Dermata Therapeutics, Inc. DRMA
1.14
(0.03)
(2.56%)
as of 25 Sep
- Market cap
- $4.7M
- P/E
- 0.0×
Follow DRMA
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(203.36%) | (194.20%) | (103.58%) | (183.89%) | |
| (150.49%) | (132.63%) | (81.31%) | (139.93%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(223.42%) | (121.45%) | (110.75%) | (242.40%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(9.10) | (8.38) | (2.15) | (2.00) | |
Free Cash Flow |
(9.34) | (7.76) | (8.30) | (8.03) | |
Piotroski F-Score |
2.00 | 2.00 | 2.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
(108.32%) | (56.44%) | (62.16%) | (101.69%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Days of Inventory on Hand |
— | — | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.06 | 1.03 | 1.17 | 0.96 | |
Depreciation/Fixed assets |
— | — | — | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(9.10) | (8.38) | (2.15) | (2.00) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates